210 related articles for article (PubMed ID: 23251632)
1. Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.
Tsuda K; Yamanaka K; Kondo M; Matsubara K; Sasaki R; Tomimoto H; Gabazza EC; Mizutani H
PLoS One; 2012; 7(12):e51819. PubMed ID: 23251632
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
[TBL] [Abstract][Full Text] [Related]
3. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils.
Yamanaka K; Umezawa Y; Yamagiwa A; Saeki H; Kondo M; Gabazza EC; Nakagawa H; Mizutani H
J Dermatol; 2014 Aug; 41(8):679-85. PubMed ID: 25099154
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab improves psoriasis without suppressing tumor antigen-specific cytotoxic T lymphocytes.
Narita M; Nishizawa Y; Iwaya S; Oiwa E; Iwabuchi M; Uchiyama T; Matsuyama A; Masuko M; Takahashi M
Int Arch Allergy Immunol; 2014; 165(1):52-60. PubMed ID: 25342444
[TBL] [Abstract][Full Text] [Related]
5. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
7. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters.
Reddy M; Torres G; McCormick T; Marano C; Cooper K; Yeilding N; Wang Y; Pendley C; Prabhakar U; Wong J; Davis C; Xu S; Brodmerkel C
J Dermatol; 2010 May; 37(5):413-25. PubMed ID: 20536646
[TBL] [Abstract][Full Text] [Related]
8. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
Benson JM; Peritt D; Scallon BJ; Heavner GA; Shealy DJ; Giles-Komar JM; Mascelli MA
MAbs; 2011; 3(6):535-45. PubMed ID: 22123062
[TBL] [Abstract][Full Text] [Related]
9. Diversion of CD4+ T cell development from regulatory T helper to effector T helper cells alters the contact hypersensitivity response.
DiIulio NA; Xu H; Fairchild RL
Eur J Immunol; 1996 Nov; 26(11):2606-12. PubMed ID: 8921946
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
[TBL] [Abstract][Full Text] [Related]
11. Concurrent treatment of chronic psoriasis and asthma with ustekinumab.
Amarnani A; Rosenthal KS; Mercado JM; Brodell RT
J Dermatolog Treat; 2014 Feb; 25(1):63-6. PubMed ID: 23469809
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
Croxtall JD
Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
de Souza A; Ali-Shaw T; Reddy SM; Fiorentino D; Strober BE
Br J Dermatol; 2013 Jan; 168(1):210-2. PubMed ID: 23278559
[TBL] [Abstract][Full Text] [Related]
14. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
[TBL] [Abstract][Full Text] [Related]
15. Effects of monomethylfumarate on dendritic cell differentiation.
Litjens NH; Rademaker M; Ravensbergen B; Thio HB; van Dissel JT; Nibbering PH
Br J Dermatol; 2006 Feb; 154(2):211-7. PubMed ID: 16433787
[TBL] [Abstract][Full Text] [Related]
16. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of ustekinumab for psoriasis.
Kumar N; Narang K; Cressey BD; Gottlieb AB
Expert Opin Drug Saf; 2013 Sep; 12(5):757-65. PubMed ID: 23745965
[TBL] [Abstract][Full Text] [Related]
18. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
19. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific T helper cells.
Carballido JM; Faith A; Carballido-Perrig N; Blaser K
Eur J Immunol; 1997 Feb; 27(2):515-21. PubMed ID: 9045925
[TBL] [Abstract][Full Text] [Related]
20. Th1, Th17, and Treg Responses are Differently Modulated by TNF-α Inhibitors and Methotrexate in Psoriasis Patients.
Furiati SC; Catarino JS; Silva MV; Silva RF; Estevam RB; Teodoro RB; Pereira SL; Ataide M; Rodrigues V; Rodrigues DBR
Sci Rep; 2019 May; 9(1):7526. PubMed ID: 31101850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
